Integration of omics analyses into GMO risk assessment in Europe: a case study from soybean field trials

Abstract In Europe, genetically modified organisms (GMOs) are subject to an authorization process including a mandatory risk assessment. According to the respective guidance by the European Food Safety Authority (EFSA), one of the pillars of this GMO risk assessment is a comparative analysis of the...

Full description

Bibliographic Details
Main Authors: Rafael Fonseca Benevenuto, Caroline Bedin Zanatta, Friedrich Waßmann, Michael F. Eckerstorfer, Sarah Zanon Agapito-Tenfen
Format: Article
Language:English
Published: SpringerOpen 2023-02-01
Series:Environmental Sciences Europe
Subjects:
Online Access:https://doi.org/10.1186/s12302-023-00715-6
_version_ 1797865300101693440
author Rafael Fonseca Benevenuto
Caroline Bedin Zanatta
Friedrich Waßmann
Michael F. Eckerstorfer
Sarah Zanon Agapito-Tenfen
author_facet Rafael Fonseca Benevenuto
Caroline Bedin Zanatta
Friedrich Waßmann
Michael F. Eckerstorfer
Sarah Zanon Agapito-Tenfen
author_sort Rafael Fonseca Benevenuto
collection DOAJ
description Abstract In Europe, genetically modified organisms (GMOs) are subject to an authorization process including a mandatory risk assessment. According to the respective guidance by the European Food Safety Authority (EFSA), one of the pillars of this GMO risk assessment is a comparative analysis of the compositional and agronomic characteristics. This targeted approach has been criticized for its limitations, as it only considers pre-determined compounds, being insufficient to assess a comprehensive range of relevant compounds, including toxins and anti-nutrients, on a case-specific basis. Strategies based on advanced untargeted omics technologies have been proposed as a potential broader approach to be implemented into the initial step of the risk assessment framework. Here, we provide an example of a step-by-step omics analysis based on systems biology approach to fit into the context of European GMO regulation. We have performed field trial experiments with genetically modified (GM) Intacta™ Roundup Ready™ 2 Pro soybean containing both cry1Ac and cp4epsps transgenic inserts and analyzed its proteomic profile against the non-GM counterpart and reference varieties. Based on EFSA’s comparative endpoint-by-endpoint approach, the proteomics analysis revealed six proteins from the GMO outside the 99% tolerance intervals of reference varieties (RVs) in the equivalence test. Interestingly, from the near-isogenic (non-GM) comparator we found as many as ten proteins to be outside of the said RVs’ equivalence limits. According to EFSA’s statistical guidelines, differences found in metabolite abundance between a GMO and its non-GM comparator would not be considered biologically relevant as all compounds of concern remained within the equivalence limits of commercial RVs. By assessing the proteomic and metabolomic data through our proposed systems biology approach, we found 70 proteins, and the metabolite xylobiose as differentially expressed between the GMO and its non-GM comparator. Biological relevance of such results was revealed through a functional biological network analysis, where we found alterations in several metabolic pathways related to protein synthesis and protein processing. Moreover, the allergenicity analysis identified 43 proteins with allergenic potential being differentially expressed in the GM soybean variety. Our results demonstrate that implementation of advanced untargeted omics technologies in the risk assessment of GMOs will enable early and holistic assessment of possible adverse effects. The proposed approach can provide a better understanding of the specific unintended effects of the genetic modification on the plant’s metabolism, the involved biological networks, and their interactions, and allows to formulate and investigate dedicated risk hypotheses in the first place. We draw conclusions on a detailed comparison with the comparative assessment according to EFSA and provide scientific arguments and examples on how the current comparative approach is not fit for purpose.
first_indexed 2024-04-09T23:06:51Z
format Article
id doaj.art-dea50b74691c4099ae28df29a201919f
institution Directory Open Access Journal
issn 2190-4715
language English
last_indexed 2024-04-09T23:06:51Z
publishDate 2023-02-01
publisher SpringerOpen
record_format Article
series Environmental Sciences Europe
spelling doaj.art-dea50b74691c4099ae28df29a201919f2023-03-22T10:41:16ZengSpringerOpenEnvironmental Sciences Europe2190-47152023-02-0135112410.1186/s12302-023-00715-6Integration of omics analyses into GMO risk assessment in Europe: a case study from soybean field trialsRafael Fonseca Benevenuto0Caroline Bedin Zanatta1Friedrich Waßmann2Michael F. Eckerstorfer3Sarah Zanon Agapito-Tenfen4CropScience Department, Federal University of Santa CatarinaCropScience Department, Federal University of Santa CatarinaDepartment of GMO Regulation and Biosafety, Federal Agency for Nature ConservationDepartment Landuse & Biosafety, Environment Agency AustriaNORCE Norwegian Research Centre AS, Climate & Environment Department, Siva InnovasjonssenterAbstract In Europe, genetically modified organisms (GMOs) are subject to an authorization process including a mandatory risk assessment. According to the respective guidance by the European Food Safety Authority (EFSA), one of the pillars of this GMO risk assessment is a comparative analysis of the compositional and agronomic characteristics. This targeted approach has been criticized for its limitations, as it only considers pre-determined compounds, being insufficient to assess a comprehensive range of relevant compounds, including toxins and anti-nutrients, on a case-specific basis. Strategies based on advanced untargeted omics technologies have been proposed as a potential broader approach to be implemented into the initial step of the risk assessment framework. Here, we provide an example of a step-by-step omics analysis based on systems biology approach to fit into the context of European GMO regulation. We have performed field trial experiments with genetically modified (GM) Intacta™ Roundup Ready™ 2 Pro soybean containing both cry1Ac and cp4epsps transgenic inserts and analyzed its proteomic profile against the non-GM counterpart and reference varieties. Based on EFSA’s comparative endpoint-by-endpoint approach, the proteomics analysis revealed six proteins from the GMO outside the 99% tolerance intervals of reference varieties (RVs) in the equivalence test. Interestingly, from the near-isogenic (non-GM) comparator we found as many as ten proteins to be outside of the said RVs’ equivalence limits. According to EFSA’s statistical guidelines, differences found in metabolite abundance between a GMO and its non-GM comparator would not be considered biologically relevant as all compounds of concern remained within the equivalence limits of commercial RVs. By assessing the proteomic and metabolomic data through our proposed systems biology approach, we found 70 proteins, and the metabolite xylobiose as differentially expressed between the GMO and its non-GM comparator. Biological relevance of such results was revealed through a functional biological network analysis, where we found alterations in several metabolic pathways related to protein synthesis and protein processing. Moreover, the allergenicity analysis identified 43 proteins with allergenic potential being differentially expressed in the GM soybean variety. Our results demonstrate that implementation of advanced untargeted omics technologies in the risk assessment of GMOs will enable early and holistic assessment of possible adverse effects. The proposed approach can provide a better understanding of the specific unintended effects of the genetic modification on the plant’s metabolism, the involved biological networks, and their interactions, and allows to formulate and investigate dedicated risk hypotheses in the first place. We draw conclusions on a detailed comparison with the comparative assessment according to EFSA and provide scientific arguments and examples on how the current comparative approach is not fit for purpose.https://doi.org/10.1186/s12302-023-00715-6Genetically modified organismSafetyBiosafetyBiotechnologyEnvironmental risk assessmentSubstantial equivalence
spellingShingle Rafael Fonseca Benevenuto
Caroline Bedin Zanatta
Friedrich Waßmann
Michael F. Eckerstorfer
Sarah Zanon Agapito-Tenfen
Integration of omics analyses into GMO risk assessment in Europe: a case study from soybean field trials
Environmental Sciences Europe
Genetically modified organism
Safety
Biosafety
Biotechnology
Environmental risk assessment
Substantial equivalence
title Integration of omics analyses into GMO risk assessment in Europe: a case study from soybean field trials
title_full Integration of omics analyses into GMO risk assessment in Europe: a case study from soybean field trials
title_fullStr Integration of omics analyses into GMO risk assessment in Europe: a case study from soybean field trials
title_full_unstemmed Integration of omics analyses into GMO risk assessment in Europe: a case study from soybean field trials
title_short Integration of omics analyses into GMO risk assessment in Europe: a case study from soybean field trials
title_sort integration of omics analyses into gmo risk assessment in europe a case study from soybean field trials
topic Genetically modified organism
Safety
Biosafety
Biotechnology
Environmental risk assessment
Substantial equivalence
url https://doi.org/10.1186/s12302-023-00715-6
work_keys_str_mv AT rafaelfonsecabenevenuto integrationofomicsanalysesintogmoriskassessmentineuropeacasestudyfromsoybeanfieldtrials
AT carolinebedinzanatta integrationofomicsanalysesintogmoriskassessmentineuropeacasestudyfromsoybeanfieldtrials
AT friedrichwaßmann integrationofomicsanalysesintogmoriskassessmentineuropeacasestudyfromsoybeanfieldtrials
AT michaelfeckerstorfer integrationofomicsanalysesintogmoriskassessmentineuropeacasestudyfromsoybeanfieldtrials
AT sarahzanonagapitotenfen integrationofomicsanalysesintogmoriskassessmentineuropeacasestudyfromsoybeanfieldtrials